Patrícia Kimáková (Author), Peter Solár (Author), Zuzana Solárová (Author), Radovan Komel (Author), Nataša Debeljak (Author)

Abstract

Erythropoietin (EPO) is the main hematopoietic hormone acting on progenitor red blood cells via stimulation of cell growth, differentiation, and anti-apoptosis. However, its receptor (EPOR) is also expressed in various non-hematopoietic tissues, including endothelium. EPO is a pleiotropic growth factor that exhibits growth stimulation and cell/tissue protection on numerous cells and tissues. In this article we review the angiogenesis potential of EPO on endothelial cells in heart, brain, and leg ischemia, as well as its role in retinopathy protection and tumor promotion. Furthermore, the effect of EPO on bone marrow and adipose tissue is also discussed.

Keywords

eritropoetin;receptor eritropoetina;rak;erythropoietin;erythropoietin receptor;cancer;

Data

Language: English
Year of publishing:
Typology: 1.02 - Review Article
Organization: UL MF - Faculty of Medicine
UDC: 616-006
COBISS: 33325785 Link will open in a new window
ISSN: 1422-0067
Views: 170
Downloads: 58
Average score: 0 (0 votes)
Metadata: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Other data

Secondary language: Slovenian
Secondary keywords: eritropoetin;receptor eritropoetina;rak;
Type (COBISS): Article
Pages: str. 1-14
Volume: ǂVol. ǂ18
Issue: ǂiss. ǂ7
Chronology: Jul. 2017
DOI: 10.3390/ijms18071519
ID: 13518212